ANTIMICROBIAL resistance was linked to $3.5 trillion in global economic losses in 2021, new research reveals.
Findings presented at IDWeek 2026 showed that drug-resistant bacterial infections were associated with economic welfare losses equivalent to 2.25% of global gross domestic product (GDP). Of this total, $835 billion, representing 0.54% of global GDP, was directly attributable to antimicrobial resistance.
Researchers assessed the global economic burden of antimicrobial resistance using disability-adjusted life-years (DALYs) from the Global Burden of Disease 2021 MICROBE tool, combined with GDP and population data.
The analysis covered 21 regions, 12 infectious syndromes, and 22 bacterial pathogens. Using a standardized Value of Lost Welfare framework, researchers estimated that antimicrobial resistance accounted for 42.6 million attributable DALYs and was associated with 177.7 million DALYs worldwide.
The distinction between attributable and associated losses reflects the additional burden caused specifically by resistance compared with the broader burden of infections involving resistant organisms.
Bloodstream infections accounted for $355 billion in directly attributable economic losses, representing 42.5% of the total. Lower respiratory infections, including pneumonia, contributed another $261 billion, or 31.3%.
Together, these infection categories were responsible for nearly three-quarters of the economic burden directly attributable to antimicrobial resistance.
Six bacterial pathogens accounted for approximately 82% of attributable losses. Klebsiella pneumoniae contributed $130 billion, followed by Streptococcus pneumoniae ($122 billion), Acinetobacter baumannii ($120 billion), Escherichia coli ($117 billion), Staphylococcus aureus ($115 billion), and Pseudomonas aeruginosa ($75 billion).
Gram-negative bacteria were responsible for more than 60% of attributable losses, highlighting their substantial contribution to the global burden of drug-resistant infections.
The greatest absolute economic losses occurred in South Asia ($101 billion), East Asia ($82 billion), and high-income North America ($70 billion).
However, Western sub-Saharan Africa experienced the greatest proportional burden, with losses equivalent to 1.42% of regional GDP.
These findings emphasize the importance of antimicrobial stewardship, improved diagnostics, vaccination, infection prevention, and equitable antibiotic access.
For US healthcare systems, the substantial burden associated with bloodstream and respiratory infections highlights potential priorities for interventions targeting drug-resistant pathogens.
Reference
Desai HD et al. Global, Regional, and Pathogen-Specific Economic Burden of Antimicrobial Resistance in 2021: A Value of Lost Welfare Analysis. Abstract 162. IDWeek, October 21–24, 2026.
Featured Image: Saiful52 on Adobe Stock.
Featured Image: Saiful52 on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
